Aura Biosciences, Inc.

Aura Biosciences, Inc.

AURA·NASDAQ

$6.88

-0.29%
HealthcareBiotechnology

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$441.69M
EPS-1.7600
P/E Ratio-3.91
Earnings Date08/06/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Aura Biosciences, Inc.

Aura Biosciences, Inc. Earnings Call Transcripts

AURA · NASDAQ

No Transcripts Available

No earnings call transcripts found for aura.